echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The third one!

    The third one!

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 19, Rongchang Biologics Claudin 18.


    According to the PharmaGo database, Rongchang Bio-HER2 ADC Vidicuzumab has been approved for marketing, and c-Met ADC RC108 and MSLN (mesothelin) ADC RC88 are in phase I clinical phase


    In June 2021, Rongchang Biologics registered the first human clinical trial of RC118 on the American Clinical Network for the treatment of solid tumors


    At present, there are 3 domestic manufacturers that declare Claudin 18.


    The target ADC drug SYSA1801 of CSPC has been clinically approved in the United States and China, and it is planned to be developed for the treatment of advanced pancreatic cancer with positive expression of Claudin 18.


    Claudin 18 (CLDN18) is a protein encoded by the CLDN 18 gene, belonging to the Tight Junction Protein family (Tight JunctionProteins), which can control the molecular flow between layers of cells


    CLDN 18.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.